Source: Eur Respir J, 51 (6) 1800844; 10.1183/13993003.00844-2018
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Sandrine Loubière, Fabrice Barlesi, Pascale Missy, Franck Morin, Pascal Auquier, Jacques Cadranel. Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times. Eur Respir J, 51 (6) 1800844; 10.1183/13993003.00844-2018

Member's Comments

No comment yet.

Related content which might interest you: Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer Source: Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018 Year: 2018 Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study Source: Eur Respir J, 51 (3) 1701467; 10.1183/13993003.01467-2017 Year: 2018 Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Source: Eur Respir J 2006; 27: 895-901 Year: 2006 Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients? Source: Eur Respir J 2002; 19: 464-468 Year: 2002 Reflex testing  is crucial for treatment decisions in advanced non small cell lung cancer (NSCLC) Source: International Congress 2017 – Chinese Programme 2017 Year: 2017 The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections Source: Eur Respir J, 56 (5) 2002595; 10.1183/13993003.02595-2020 Year: 2020 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages Source: Eur Respir Rev, 29 (155) 190052; 10.1183/16000617.0052-2019 Year: 2020 Modern profiling of advanced lung cancer at the primary diagnosis and during therapy Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Towards personalized treatment in non-small-cell lung carcinoma Source: Virtual Congress 2020 – Management issues in thoracic oncology Year: 2020 Delays in the diagnosis and treatment of non-small cell lung cancer Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010 The evaluation of surgical results in pT0-pT1 non-small cell lung carcinoma after induction therapy Source: Annual Congress 2011 - General thoracic surgery II Year: 2011